Optimal use of phosphate binders in chronic kidney disease

Author： Sonikian Makrouhi Papachristou Evangelos Goumenos Dimitrios S

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.18, 2013-12, pp. : 2521-2532

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?

By Malindretos Pavlos

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2255-2256

Informa Healthcare

Access to resources Recommend Favorite

Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles

By Locatelli Francesco Del Vecchio Lucia Violo Leano Pontoriero Giuseppe

Expert Opinion on Drug Safety, Vol. 13, Iss. 5, 2014-05 ,pp. : 551-561

Informa Healthcare

Access to resources Recommend Favorite

Lanthanum carbonate: a guide to its use as a phosphate-binding agent in patients with chronic kidney disease

Drugs & Therapy Perspectives, Vol. 26, Iss. 8, 2010-08 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Safety of New Phosphate Binders for Chronic Renal Failure

By Loghman-Adham M.

Drug Safety, Vol. 26, Iss. 15, 2003-01 ,pp. : 1093-1115

Adis International

Access to resources Recommend Favorite

Use of Enoxaparin in Patients with Chronic Kidney Disease: Safety Considerations

By Brophy Donald F. Sica Domenic A.

Drug Safety, Vol. 30, Iss. 11, 2007-01 ,pp. : 991-994

Adis International

Access to resources Recommend Favorite